UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or orga ...

"I am excited to announce another record revenue quarter in the third quarter of fiscal year 2024," said Jim Cunniff, President, and Chief Executive officer. "Our company continues to operate at a high level, further driving the adoption of our best-in-class product, backed by careful commercial expansion and excellent operational efficiency. Our strategy has again generated double-digit revenue growth, with significant operating leverage that is resulting in strong profitability. The team remains focused o ...

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Sidoti March Small-Cap Virtual Conference on March 13-14, 2024. Electromed’s management team will present at 10:45 a.m. Eastern Time on Wednesday, March 13, 2024. A live and archived webcast of the even ...

ljubaphoto Electromed, Inc. (NYSE:ELMD) recently reported an impressive quarter, and noted beneficial expectations for the year 2024. With a total market opportunity of close to 4.2 million patients suffering from Bronchiectasis, I assumed that the total market opportunity could be around $8.4 billion. Given the current revenue line, there is significant room for improvement thanks to direct-to-consumer and medical marketing as well as internationalization efforts. If we also include the stock repurchas ...

Financial Data and Key Metrics Changes - Total net revenue for Q2 2024 reached $13.7 million, representing a 17% year-over-year growth from Q2 2023, marking the fifth consecutive quarter of mid-teens or better revenue growth [23][41] - Operating income for the quarter was a record $2.3 million, a growth of 78% over the same period in the prior fiscal year [3] - Gross profit increased to $10.5 million, or 77% of net revenues for the quarter, compared to $8.7 million or 74% of net revenues in Q2 FY '23 [32] Business Line Data and Key Metrics Changes - Home care revenue for the quarter was $12.7 million, an increase of 18% over Q2 last year, driven by an increase in sales territories and efficiencies in the reimbursement department [31] - Hospital revenue increased year-over-year by 5% to $619,000, attributed to the addition of a strategic account manager [11] - International revenue increased year-over-year by 69% to $122,000, although growing the international business is not currently a primary focus [11] Market Data and Key Metrics Changes - There are approximately 824,000 patients in the U.S. diagnosed with bronchiectasis, with a significant revenue opportunity estimated at $2.3 billion if all managed patients were prescribed HFCWO therapy [6] - The company is focused on increasing awareness among healthcare providers regarding the benefits of HFCWO therapy for bronchiectasis patients [6][43] Company Strategy and Development Direction - The company aims to continue expanding its sales force, planning to hire 5 additional representatives in the second half of the fiscal year to deepen market penetration [27] - A new distribution agreement with Marathon Medical is expected to enhance access to products for government facilities, improving the ordering process [28] - The company is committed to developing guidelines for treating bronchiectasis patients with HFCWO, engaging with key opinion leaders and societies [27][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategies, highlighting the importance of operational excellence and customer service [24] - The company is generating cash from operations and has no debt, positioning it uniquely in the microcap medtech space [25] - Management anticipates improvements in the hospital market, although the selling cycle is longer compared to the home market [46] Other Important Information - The company had $10.4 million in cash and $23 million in accounts receivable as of December 31, 2023, achieving a working capital of $32.7 million [41] - Research and development expenses decreased by 31% to $107,000, primarily due to reduced costs associated with Clearway product development [12] Q&A Session Summary Question: Transition of patients onto HFCWO therapy - Management noted that there is a critical need for increased awareness among physicians regarding bronchiectasis, which is essential for getting patients onto HFCWO therapy sooner [15][43] Question: Sales force training and new strategy effectiveness - Management confirmed plans to add 5 new sales representatives and refine training protocols based on feedback from previous training classes [17][36] Question: Growth in the hospital market with Clearway - Management acknowledged that the hospital market is still nascent, with growth expected but dependent on building relationships with pulmonologists and distributors [38][46]

Financial Performance - Net revenues for the three months ended December 31, 2023, were $13,689,000, an increase of $1,960,000 or 16.7% compared to the same period in 2022[75]. - Gross profit for the three months ended December 31, 2023, was $10,545,000, representing 77.0% of net revenues, up from 74.0% in the same period last year[80]. - Net income for the three months ended December 31, 2023, was $1,674,000, compared to $977,000 for the same period in the prior year, driven by homecare revenue growth and increased gross profit margin[90]. Revenue Sources - Homecare revenue increased by $1,936,000, or 18.0%, for the three months ended December 31, 2023, driven by increased direct sales territories and efficiencies in the reimbursement department[76]. Expenses - Selling, general and administrative expenses increased by $921,000, or 12.7%, for the three months ended December 31, 2023, compared to the same period in the prior year[81]. - Research and development expenses decreased by $47,000, or 30.5%, for the three months ended December 31, 2023, primarily due to reduced costs associated with the SmartVest Clearway platform development[86]. Cash Flow and Liquidity - Cash provided by operating activities for the six months ended December 31, 2023, was $3,227,000, consisting of net income of $1,829,000 and non-cash expenses of $1,214,000[91]. - The company has a working capital of $32,692,000, which is expected to meet anticipated liquidity needs for the next twelve months[95]. - The line of credit available as of December 31, 2023, was $2,500,000, with no outstanding principal balance[96]. - The company believes its cash, cash equivalents, and cash flows from operations will be sufficient to meet working capital and capital expenditure requirements for fiscal 2024 and the foreseeable future[100]. - The company expects to finance planned equipment purchases through cash flows from operations or borrowings under its credit facility, with potential additional debt if unforeseen capital needs arise[99]. - The company is evaluating projected expenditures against available cash and considering financing alternatives to meet cash requirements[100]. Taxation - The effective tax rate for the three months ended December 31, 2023, was 28.8%[88]. Risks and Challenges - Risks affecting future performance include the ability to obtain reimbursement from Medicare and Medicaid, potential component shortages, and regulatory compliance challenges[102]. - The company faces risks from new competitors, adverse economic conditions, and the need for salesforce expansion[102]. - The company anticipates potential impacts from international healthcare regulations on its business operations[102]. - Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections[101]. Strategic Focus - The company is focused on maintaining regulatory compliance and gaining future approvals for its products[102]. - The company is committed to protecting and expanding its intellectual property portfolio as part of its growth strategy[102].

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 second quarter ended December 31, 2023, on February 13, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by ...

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE American: ELMD) today announced it has entered into a distribution agreement with Marathon Medical Corp., a medical supply distribution company and service-disabled veteran-owned small business (SDVOSB). SmartVest® Airway Clearance System, which is designed for High Frequency Chest Wall Oscillation (“HFCWO”) therapy, a clinically proven therapy that helps clear the lungs of excess secretions, thereby reducing the risk of respiratory infections and h ...

Electromed, Inc. (NYSE:ELMD) Q1 2024 Results Conference Call November 7, 2023 5:00 PM ET Company Participants Mike Cavanaugh - IR, ICR Westwicke Jim Cunniff - President and CEO Brad Nagel - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Operator Good day, and welcome to the Electromed First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note today’s event is being recorded. I would now like to turn the conference over to Mike Cavanaugh with ICR Westwicke. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 41-1732920 (State or other jurisdiction ...